• Prescribing Information
  • Medical Information
  • Patient Site
  • Order Prevnar 20TM
  • Storage, handling, and administration

    Help protect your patients with a single dose

    • To minimize resuspension time, syringes should be stored in the refrigerator horizontally
    • Approved as a single dose
    • Packaged as a pre-filled syringe

    Dosage and administration

    For intramuscular administration only 

    Preparation 
    ​​​​​
    ​​​​​​​Do not mix Prevnar 20™ with other vaccines/products in the same syringe.

    Step 1. Resuspend drug product

    Hold the pre-filled syringe horizontally between the thumb and the forefinger and shake vigorously until the vaccine is a homogeneous white suspension. Do not use the vaccine if it cannot be re-suspended.
    ​​​​​​​

    Step 2. Visual inspection

    Visually inspect the vaccine for large particulate matter and discoloration prior to administration. Do not use if large particulate matter or discoloration is found. If the vaccine is not a homogeneous suspension, repeat Steps 1 and 2.
    ​​​​​​​

    Step 3. Remove syringe cap

    Remove the syringe cap by slowly turning the cap counterclockwise while holding the Luer lock adapter. 

    Avoid pressing the syringe plunger rod while removing the syringe cap.​​​​​​​

    Step 4. Attach a sterile needle

    Hold the Luer lock adapter and attach a needle appropriate for intramuscular administration to the pre-filled syringe by turning clockwise.

    Administration

    For intramuscular injection only. 
    ​​​​​​​
    Each 0.5 mL dose is to be injected intramuscularly using a sterile needle attached to the supplied pre-filled syringe. 

    Storage and handling 

    • After shipping, Prevnar 20™ may arrive at temperatures between 2 °C to 25 °C (36 ºF to 77 ºF)
    • Upon receipt, store refrigerated at 2 °C to 8 °C (36 ºF to 46 ºF)
    • Syringes should be stored in the refrigerator horizontally to minimize the resuspension time
    • Do not freeze. Discard if the vaccine has been frozen
    • Prevnar 20™ should be administered as soon as possible after being removed from refrigeration
    • Prevnar 20™ can be administered provided total (cumulative multiple excursions) time out of refrigeration (at temperatures between 8 °C and 25 °C) does not exceed 96 hours. Cumulative multiple excursions between 0 °C and 2 °C are also permitted as long as the total time between 0 ºC and 2 ºC does not exceed 72 hours. These are not, however, recommendations for storage
    • The tip cap and plunger stopper of the pre-filled syringe are not made with natural rubber latex    

    Reference: 1. Prevnar 20™ (Pneumococcal 20-valent Conjugate Vaccine) Prescribing Information, Wyeth Pharmaceuticals LLC, 2021.

    This site is intended only for US residents. The products discussed in this site may have different product labeling in different countries. The information provided is for educational purposes only and is not intended to replace discussions with a healthcare provider.

    ​​​​​Manufactured by Wyeth Pharmaceuticals LLC.
    © 2021 Pfizer Inc.

    ​​​​​​​​​​​​All rights reserved.

    Marketed by Pfizer Inc.
    November 2021

    ​​​​​Manufactured by Wyeth Pharmaceuticals LLC.
    Marketed by Pfizer Inc.
    © 2021 Pfizer Inc. ​​​​​All rights reserved. November 2021

    Indication

    • Prevnar 20™ is indicated for active immunization for the prevention of pneumonia and invasive disease caused by Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14, 15B, 18C, 19A, 19F, 22F, 23F, and 33F in adults 18 years of age and older
    • This indication for the prevention of pneumonia caused by S. pneumoniae serotypes 8, 10A, 11A, 12F, 15B, 22F, and 33F is approved under accelerated approval based on immune responses as measured by opsonophagocytic activity (OPA) assay. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial 
      ​​​​​​​
      • Severe allergic reaction (e.g., anaphylaxis) to any component of Prevnar 20™, Prevnar 13®, or to diphtheria toxoid is a contraindication
      • Safety and immunogenicity data on Prevnar 20™ are not available for individuals in immunocompromised groups and vaccination should be considered on an individual basis. Based on experience with pneumococcal vaccines, individuals with altered immunocompetence may have reduced immune responses to Prevnar 20™
      • Immunocompromised individuals or individuals with impaired immune responsiveness due to the use of immunosuppressive therapy may have reduced antibody response to Prevnar 13®
      • For Prevnar 20™, in adults 18 years of age and older, the most commonly reported solicited adverse reactions (>10%) were pain at the injection site, muscle pain, fatigue, headache, and arthralgia. Additionally, injection site swelling was also reported (>10%) in adults 18 through 59 years of age 
      • For Prevnar 13®, in adults 18 years of age and older, the most commonly reported solicited adverse reactions (>5%) were pain, redness, and swelling at the injection site, limitation of arm movement, fatigue, headache, muscle pain, joint pain, decreased appetite, vomiting, fever, chills, and rash 

      Patients should always ask their healthcare providers for medical advice about adverse events. You are encouraged to report negative side effects of vaccines to the US Food and Drug Administration (FDA) and the Centers for Disease Control and Prevention (CDC). Visit http://www.vaers.hhs.gov or call 1-800-822-7967.

      Please click for Prevnar 20™ Full Prescribing Information.

      Please click for Prevnar 13® Full Prescribing Information.


      • Prevnar 20™ is indicated for active immunization for the prevention of pneumonia and invasive disease caused by Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14, 15B, 18C, 19A, 19F, 22F, 23F, and 33F in adults 18 years of age and older 
      • The indication of Prevnar 20™ for the prevention of pneumonia caused by S. pneumoniae serotypes 8, 10A, 11A, 12F, 15B, 22F, and 33F is approved under accelerated approval based on immune responses as measured by opsonophagocytic activity (OPA) assay. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial 
      • Prevnar 13® is indicated for active immunization for the prevention of pneumonia and invasive disease caused by Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F in adults 18 years of age and older

      Prevnar 13® Limitations of Use: Prevnar 13® will only help protect against S. pneumoniae serotypes in the vaccine